LEO Pharma announces annual results 2021
17.3.2022 13:00:00 CET | LEO Pharma | Press release
Growth in net sales
Net sales grew 5% to DKK 9,957 million when excluding discontinued and divested products. Strategic psoriasis products Enstilar® and Kyntheum® continued to grow and gain market shares.
- Sales of Kyntheum® outperformed market growth rates in biologics for psoriasis growing 32% to DKK 615 million.
- Revenue of Enstilar® grew 15% to DKK 1,292 million.
- Products in our Eczema/Skin infection range grew 6% to DKK 2,819 million.
- Revenue for Eczema grew 14%, driven by both Protopic® and our Advantan® portfolio growing by 11% and 12%, respectively.
Operating loss higher than financial guidance
EBIT: Operating loss of DKK 4,156 million, higher than financial guidance due to continued investments in R&D and launch of tralokinumab, delay of Adbry™ (US tralokinumab brand name) approval in the US, write-off of patidegib and introduction of long-term efficiencies.
- 23% of revenues invested in R&D
- Write-off of patidegib amounts to DKK 435 million
Significant advancement in R&D pipeline in line with 2030 strategy
LEO Pharma’s R&D pipeline progressed significantly and achieved important milestones to support future growth.
- EMA and FDA approval of tralokinumab in atopic dermatitis
- Delgocitinib, a topical pan-JAK inhibitor for treatment of chronic hand eczema progressed to phase 3
- Anti IL-22R, an anti-inflammatory monoclonal antibody for atopic dermatitis, progressed to phase 2A
- H4R, a systemic anti-pruritic and anti-inflammatory H4 receptor antagonist for atopic dermatitis, progressed to phase 2A
- IL-17 small molecule modulator for treatment of psoriasis moved from pre-clinical stage to phase 1
Outlook for 2022
In 2022 LEO Pharma will continue its focus on the launch of Adtralza®/Adbry™ across markets and delivering on the recently announced transformation and efficiency program which is expected to show the company delivering double-digit growth from 2023. For 2022, LEO Pharma anticipates annual revenue growth of 3-5% to DKK 10.2-10.4 billion, driven by the launch of tralokinumab and growth in our strategic products. We will continue to focus on profitability improvements for the established portfolio and to invest significantly in innovative research and development activities. Furthermore, costs related to product launches will increase significantly in 2022. LEO Pharma expects this to lead to an operating loss (EBIT) of DKK 3.1-3.3 billion in 2022.
Acting CEO of LEO Pharma, Anders Kronborg commented:
“2021 was a year dominated by transformation and progressing diligently on our strategy. While our operating result did not meet financial guidance, we are satisfied to see growth in net sales and in sales of our strategic psoriasis products Enstilar® and Kyntheum®, which both outperformed market growth. The approvals of tralokinumab in US and Europe, and filing for marketing authorization in Japan, mark other important milestones to see LEO Pharma starting to deliver increased growth and positive results from 2023 as outlined in our strategy. Also, 2021 saw LEO Pharma welcome a new Chair of the board, a new minority investor and introducing an employee share purchase program which are all proof points of the potential of the strategy we have laid out. In 2022, we will continue to invest in launching tralokinumab, accelerating our R&D efforts through our own R&D operations as well as through acquisitions and partnerships.”
Key figures
|
|
|||
|
DKK million |
2021 |
2020 |
Growth |
|
Revenue |
9,957 |
10,133 |
(2)% |
|
Revenue adjusted for contract manufacturing business |
9,570 |
9,122 |
5% |
|
EBITDA |
(1,957) |
521 |
|
|
Operating profit (EBIT) |
(4,156) |
(726) |
|
|
Net profit |
(4,868) |
(951) |
|
|
R&D investments (% of revenue) |
23% |
21% |
|
Annual report 2021
The full results are available in the LEO Pharma Annual Report 2021 on the company’s website at: LEO Pharma Annual Report 2021
Changes to LEO Pharma’s Board of Directors
At LEO Pharma’s Annual General Meeting 2022, Vice Chair Anders Ekblom and board member Birgitta Stymne Göransson did not stand for re-election and will leave LEO Pharma’s Board of Directors. Jesper Mailind was elected as Vice Chair by the general meeting.
Contacts
Media contact:
Henrik Heskjær
hdtdk@leo-pharma.com
+45 3140 6180
About LEO Pharma
About LEO Pharma
LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 5,800 people, serving millions of patients across the world. In 2021, the company generated net sales of DKK 9,957 million.
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma presents new data on delgocitinib cream at EADV 2026 highlighting real-world outcomes in adults and new adolescent data in Chronic Hand Eczema (CHE)1.10.2026 12:00:00 CEST | Pressemeddelelse
Interim results from the German REACHED study provide the first real-world evidence on the effectiveness of delgocitinib cream in adults with moderate to severe Chronic Hand Eczema (CHE), with 28.6% of patients assessed as clear or almost clear after eight weeks of treatment, from none at baseline.1 New post hoc analyses from the phase 3 DELTA TEEN trial show greater reductions in daily HESD itch and pain scores with delgocitinib cream than with cream vehicle in adolescents aged 12-17 with moderate to severe CHE.2 In an oral presentation, new post hoc analyses from DELTA TEEN show that a higher proportion of adolescents reported no impact on quality of life at Week 16 with delgocitinib cream than with cream vehicle (27.0% vs 0%)3
LEO Pharma presents new tralokinumab data at EADV 2026 highlighting real-world outcomes and quality of life in adults and adolescents with atopic dermatitis (AD) involving high-burden areas1.10.2026 10:30:00 CEST | Pressemeddelelse
New findings from a subgroup analysis of the 12-month TRACE study show that more than 70% of adults whose Atopic Dermatitis (AD) affected multiple high-burden areas – such as the head and neck, hands and feet, or genitals – had reduced involvement of those areas after 12 months of treatment with tralokinumab.1 New pre-specified and post hoc analyses from the phase 3 ADHAND trial show significantly greater improvements in quality of life, daily function and sleep at Week 16 with tralokinumab monotherapy than with placebo in adults with AD and moderate-to-severe hand involvement, with the two treatment groups separating within two weeks.2,3 In a post hoc analysis, adolescents aged 12-17 years treated across the phase 3 ECZTRA 6 trial and its ECZTEND extension, response rates remained high and stable through most of the extension period, and no new safety concerns were identified.5
LEO Pharma to showcase its broadest ever scientific program at EADV 202624.9.2026 09:00:00 CEST | Pressemeddelelse
LEO Pharma will present 28 accepted abstracts at the 2026 European Academy of Dermatology and Venereology Congress, taking place from 30 September to 3 October in Vienna, Austria. The EADV 2026 program reflects the strength and breadth of LEO Pharma’s portfolio, showcasing what’s now and what’s next in medical dermatology with new evidence across nine disease areas, six routes of administration and nine modes of action; including biologic injectables, topical formulations, and covering data across established dermatology brands and new innovation. The program underscores LEO Pharma’s continued commitment to advancing medical dermatology through evidence that addresses both highly prevalent chronic skin diseases and complex or rare, hard-to-treat conditions with significant unmet needs.
LEO Pharma receives positive CHMP opinion recommending Anzupgo® (delgocitinib) cream for adolescents with moderate to severe chronic hand eczema in the EU18.9.2026 10:00:00 CEST | Pressemeddelelse
The Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the use of Anzupgo® (delgocitinib) cream to adolescents aged 12 to 17 years with moderate to severe chronic hand eczema for whom topical corticosteroids are inadequate or inappropriate. If approved by the European Commission, Anzupgo® would become the first therapy in the EU specifically approved for adolescents with moderate to severe chronic hand eczema, a patient population for whom there are currently no specifically approved treatment options. The positive CHMP opinion is supported by results from DELTA TEEN, a phase 3 trial investigating the efficacy and safety of Anzupgo® in adolescents with moderate to severe chronic hand eczema.1
LEO Pharma announces FDA acceptance of dersimelagon NDA with Priority Review and closes acquisition from Tanabe Pharma18.9.2026 09:00:00 CEST | Pressemeddelelse
The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for dersimelagon for filing and granted it Priority Review, with a Prescription Drug User Fee Act (PDUFA) date expected by the end of February 2027. LEO Pharma has successfully closed the acquisition of dersimelagon from Tanabe Pharma, strengthening its late-stage pipeline and further leveraging its global dermatology platform. Dersimelagon is an investigational, once-daily oral melanocortin 1 receptor (MC1R) agonist for the treatment of erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), two rare genetic skin diseases with significant unmet medical need.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom